Back to Search Start Over

Post COVID-19 irritable bowel syndrome.

Authors :
Marasco G
Cremon C
Barbaro MR
Cacciari G
Falangone F
Kagramanova A
Bordin D
Drug V
Miftode E
Fusaroli P
Mohamed SY
Ricci C
Bellini M
Rahman MM
Melcarne L
Santos J
Lobo B
Bor S
Yapali S
Akyol D
Sapmaz FP
Urun YY
Eskazan T
Celebi A
Kacmaz H
Ebik B
Binicier HC
Bugdayci MS
Yağcı MB
Pullukcu H
Kaya BY
Tureyen A
Hatemi İ
Koc ES
Sirin G
Calıskan AR
Bengi G
Alıs EE
Lukic S
Trajkovska M
Hod K
Dumitrascu D
Pietrangelo A
Corradini E
Simren M
Sjölund J
Tornkvist N
Ghoshal UC
Kolokolnikova O
Colecchia A
Serra J
Maconi G
De Giorgio R
Danese S
Portincasa P
Di Sabatino A
Maggio M
Philippou E
Lee YY
Salvi D
Venturi A
Borghi C
Zoli M
Gionchetti P
Viale P
Stanghellini V
Barbara G
Source :
Gut [Gut] 2022 Dec 09. Date of Electronic Publication: 2022 Dec 09.
Publication Year :
2022
Publisher :
Ahead of Print

Abstract

Objectives: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction after hospitalisation for SARS-CoV-2 infection.<br />Design: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires.<br />Results: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls.<br />Conclusion: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls.<br />Trial Registration Number: NCT04691895.<br />Competing Interests: Competing interests: None declared.<br /> (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)

Details

Language :
English
ISSN :
1468-3288
Database :
MEDLINE
Journal :
Gut
Publication Type :
Academic Journal
Accession number :
36591612
Full Text :
https://doi.org/10.1136/gutjnl-2022-328483